Search

Your search keyword '"Bonino F"' showing total 1,244 results
Start Over Author "Bonino F"
1,244 results on '"Bonino F"'

3. T.12.2: THE LEVELS OF AFP, PIVKA-II AND GPC-3 SERUM BIOMARKERS AT DIAGNOSIS CORRELATE WITH HCC CLINICAL-PATHOLOGICAL FEATURES AND WITH OVERALL SURVIVAL

Author

Damone, F., primary, Caviglia, G.P., additional, Colombatto, P., additional, Ricco, G., additional, Oliveri, F., additional, Gaia, S., additional, Romagnoli, V., additional, Cavallone, D., additional, Rolle, E., additional, Coco, B., additional, Salvati, A., additional, Surace, L., additional, Carucci, P., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2024
Full Text
View/download PDF

4. Artificial Intelligence and liver: Opportunities and barriers

Author

Balsano, C, Burra, P, Duvoux, C, Alisi, A, Piscaglia, F, Gerussi, A, Brunetto, M, Bonino, F, Montalti, R, Campanile, S, Persico, M, Alvaro, D, Santini, S, Invernizzi, P, Carbone, M, Masarone, M, Eccher, A, Siciliano, B, Vento, M, Ficuciello, F, Cabitza, F, Penasa, S, Donatelli, P, Balsano C., Burra P., Duvoux C., Alisi A., Piscaglia F., Gerussi A., Brunetto M. R., Bonino F., Montalti R., Campanile S., Persico M., Alvaro D., Santini S., Invernizzi P., Carbone M., Masarone M., Eccher A., Siciliano B., Vento M., Ficuciello F., Cabitza F., Penasa S., Donatelli P., Balsano, C, Burra, P, Duvoux, C, Alisi, A, Piscaglia, F, Gerussi, A, Brunetto, M, Bonino, F, Montalti, R, Campanile, S, Persico, M, Alvaro, D, Santini, S, Invernizzi, P, Carbone, M, Masarone, M, Eccher, A, Siciliano, B, Vento, M, Ficuciello, F, Cabitza, F, Penasa, S, Donatelli, P, Balsano C., Burra P., Duvoux C., Alisi A., Piscaglia F., Gerussi A., Brunetto M. R., Bonino F., Montalti R., Campanile S., Persico M., Alvaro D., Santini S., Invernizzi P., Carbone M., Masarone M., Eccher A., Siciliano B., Vento M., Ficuciello F., Cabitza F., Penasa S., and Donatelli P.

Abstract

Artificial Intelligence (AI) has recently been shown as an excellent tool for the study of the liver; however, many obstacles still have to be overcome for the digitalization of real-world hepatology. The authors present an overview of the current state of the art on the use of innovative technologies in different areas (big data, translational hepatology, imaging, and transplant setting). In clinical practice, physicians must integrate a vast array of data modalities (medical history, clinical data, laboratory tests, imaging, and pathology slides) to achieve a diagnostic or therapeutic decision. Unfortunately, machine learning and deep learning are still far from really supporting clinicians in real life. In fact, the accuracy of any technological support has no value in medicine without the support of clinicians. To make better use of new technologies, it is essential to improve clinicians’ knowledge about them. To this end, the authors propose that collaborative networks for multidisciplinary approaches will improve the rapid implementation of AI systems for developing disease-customized AI-powered clinical decision support tools. The authors also discuss ethical, educational, and legal challenges that must be overcome to build robust bridges and deploy potentially effective AI in real-world clinical settings.

Published
2023

5. Characterization of Metal Centers in Zeolites for Partial Oxidation Reactions

Author

Berlier, G., Crocellà, V., Signorile, M., Borfecchia, E., Bonino, F., Bordiga, S., Mingos, David Michael P., Series Editor, Duan, Xue, Editorial board, Gade, Lutz H., Editorial board, Lu, Yi, Editorial advisor, Neese, Frank, Editorial advisor, Pariente, Joaquin Perez, Editorial advisor, Schneider, Sven, Editorial advisor, Stalke, Dietmar, Editorial advisor, Pérez Pariente, Joaquín, editor, and Sánchez-Sánchez, Manuel, editor

Published
2018
Full Text
View/download PDF

6. The application of artificial intelligence in hepatology: A systematic review

Author

Balsano, C, Alisi, A, Brunetto, M, Invernizzi, P, Burra, P, Piscaglia, F, Alvaro, D, Bonino, F, Carbone, M, Faita, F, Gerussi, A, Persico, M, Santini, S, Zanetto, A, Balsano C., Alisi A., Brunetto M. R., Invernizzi P., Burra P., Piscaglia F., Alvaro D., Bonino F., Carbone M., Faita F., Gerussi A., Persico M., Santini S. J., Zanetto A., Balsano, C, Alisi, A, Brunetto, M, Invernizzi, P, Burra, P, Piscaglia, F, Alvaro, D, Bonino, F, Carbone, M, Faita, F, Gerussi, A, Persico, M, Santini, S, Zanetto, A, Balsano C., Alisi A., Brunetto M. R., Invernizzi P., Burra P., Piscaglia F., Alvaro D., Bonino F., Carbone M., Faita F., Gerussi A., Persico M., Santini S. J., and Zanetto A.

Abstract

The integration of human and artificial intelligence (AI) in medicine has only recently begun but it has already become obvious that intelligent systems can dramatically improve the management of liver diseases. Big data made it possible to envisage transformative developments of the use of AI for diagnosing, predicting prognosis and treating liver diseases, but there is still a lot of work to do. If we want to achieve the 21st century digital revolution, there is an urgent need for specific national and international rules, and to adhere to bioethical parameters when collecting data. Avoiding misleading results is essential for the effective use of AI. A crucial question is whether it is possible to sustain, technically and morally, the process of integration between man and machine. We present a systematic review on the applications of AI to hepatology, highlighting the current challenges and crucial issues related to the use of such technologies.

Published
2022

7. The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects clinic-pathologic differences.

Author

Damone, F., Colombatto, P., Pinna, A., Ricco, G., Cavallone, D., Petralli, G., Vukotic, R., Coco, B., Surace, L., Romagnoli, V., Oliveri, F., Bonino, F., and Brunetto, M.R.

Abstract

Chronic Hepatitis D (CHD) infection causes an additional pathologic burden in patients (pts) with Chronic Hepatitis B Virus (CHB), leading to worse outcomes. We evaluated liver (LSM) and spleen (SSM) stiffness measurements in CHB and CHD pts to assess the added value of SSM in this clinical setting. We studied 119-HBsAg+ pts, 71-CHB and 48-CHD [30(42.3%) and 27(56.3%) with cirrhosis, respectively] undergoing regular follow-up at the Hepatology-Unit of Pisa University Hospital. Physical examination, ultrasound scan, LSM and SSM (FibroScan-Echosens,France) were performed on the same day, liver biochemistry and virological assays within one week. Demographical, clinical and laboratory features are reported in Table-1a. Median LSM was lower in CHB than in CHD pts [6.2(2.8–71) vs 8.1(2.8–33.1) kPa, (p=0.004)], whereas SSM was similar [25.6(9.3–87.6) vs. 26.8(4.8–100) kPa, p=0.569]. Median SSM/LSM-ratio was lower in CHD than in CHB [2.98(1.00-9.64) vs 3.88(1.09-16.25), p=0.003]. Median spleen diameter (SD) was similar between CHB and CHD (11.0(7.0-18.0) cm vs 12.0(6.5-23.0)cm, p=0.079). CHD showed a significantly lower SD/LSM-ratio [1.33(0.36-3.89) vs 1.78(0.21-4.08), p=0.007], but similar SD/SSM ratio [0.44(0.14-2.06) vs 0.43(0.14-1.07), p=0.688]. Also in cirrhotic pts, median LSM was significantly lower in CHB pts [9.7(3.7-71) vs 13.3(5.6-33.1) kPa,p=0.022], whereas SSM was similar [34.0(9.9-87.6) vs 33.3(14.5-100) kPa,p=0.842]. The SD/LSM-ratio showed a trend to be lower in cirrhotic-CHD [0.92(0.36-2.09) vs 1.20(0.21-2.89); p=0.054]. In CHD, SSM correlated better with LSM, SD and PLT-count overall and in cirrhotics (table 1-b). Combining LSM and SSM provides a useful differential clinic pathologic characterization of liver disease in pts with CHB and CHD. The significantly lower SD/LSM-ratio found in CHD pts, suggests the specific role of HDV induced necro-inflammation as a driver of disease progression with splenomegaly and platelet count reduction. Longer follow up in CHD treated patients are needed to define the curative impact of the current antivirals. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

14. Cancer cells and tumor vasculature dynamics analyzed by bio-mathematical modeling in HCC patients with different response to TKIs, TACE and TARE

Author

Damone, F., primary, Colombatto, P., additional, Ricco, G., additional, Oliveri, F., additional, Civitano, L., additional, Romagnoli, V., additional, Cavallone, D., additional, Demirtas, C.O., additional, Boraschi, P., additional, Scalise, P., additional, Crocetti, L., additional, Bargellini, I., additional, Coco, B., additional, Salvati, A., additional, Surace, L., additional, Boni, G., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2022
Full Text
View/download PDF

20. Liver and spleen stiffness measure by transient elastograghy: a promising tool for the clinical management of patients after Fontan-type surgery circulation.

Author

Coco, B., Ali, L. Ait, Petralli, G., De Stefano, L., Colombatto, P., Vukotic, R., Salvati, A., Bonino, F., Festa, P., and Brunetto, M.R.

Abstract

Haemodynamic changes after Fontan palliation in infant patients with univentricular heart promote so-called Fontan-associated-liver-disease (FALD). FALD is not adequately monitored by traditional liver clinical scores (e.g. MELD-XI, VAST score) and progression risk biomarkers and non-invasive tools are missing. Liver and spleen stiffness (LSM and SSM) measured by transient elastography might be useful technique. Aim was to study correlations between LSM-SSM and FALD stages in adult post-Fontan patients. 31 consecutive pts with compensated FALD (median age 27 y, 23.1-37.7 y; 8 F) were studied. We recorded liver morphology/structure by ultrasound-scan, LSM and SSM (Fibroscan®), biochemical liver tests, radiologic and/or upper endoscopic signs of portal hypertension and cardiological functional parameters. Median LSM and SSM were 16.8 (13.7-24.1) kPa and 30.4 (24.4-42.8) kPa respectively and significantly correlated (r=0.492, p=0.0058). LSM correlated with g-GT levels (r=0.452, p=0.0139) and caudate lobe hypertrophy (r=0.449; p=0.0127), while SSM did't. Patients with advanced liver involvement had significantly higher LSM [18.5 (16.6-38.8) kPa in VAST>1 vs 16.2 (13.1-20.8) kPa in VAST£1 pts (p=0.0499)]. LSM for VAST score>1 identified an AUROC of 0.750 (p=0.0136) and a 16.4 kPa cut off with 100% sensitivity and 50% specificity. SSM was not correlated with FALD stage. SSM was correlated to left ventriculus disfunction in logistic regression (r=0.384, p=0.461) and it was higher in pts on beta-blockers (34.0 vs 26.7 kPa, p=0.0294) or diuretics (39.1 vs 26.7 kPa, p=0.0401) reflecting a worse hemodynamic condition. LSM and SSM appear promising tools for the clinical management of pts with Fontan circulation. LSM >16.4 kPa predicted with high sensitivity advanced FALD. SSM is significantly higher in patients requiring on diuretics, suggesting its potential role in the prognostic stratification of this challenging population. These preliminary results prompt prospective studies on larger cohorts of pts after Fontan's surgery. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

21. Prognostic value of a composite biomarker score for predicting overall survival in HCC patients.

Author

Damone, F., Caviglia, G.P., Colombatto, P., Oliveri, F., Ricco, G., Guariglia, M., Gaia, S., Romagnoli, V., Cavallone, D., Rolle, E., Carucci, P., Bonino, F., and Brunetto, M.R.

Abstract

Despite advances in diagnosis and treatment of Hepatocellular Carcinoma (HCC), its management remains challenging. Tumor stage and liver function, that impact overall survival (OS), currently guide treatment algorithms. Lacking histology in most cases, serum biomarkers might provide additional insights to characterize tumor biology. Alpha-fetoprotein (AFP), Prothrombin induced by vitamin K absence-II (PIVKA-II), and glypican-3 (GPC-3) have been separately used for diagnosis and monitoring, whether their measure can better stratify survival is unknown. In this retrospective cohort 275 patients admitted at the Hepatology-Unit of Pisa University Hospital and at the Gastroenterology-Unit of the Molinette-Hospital, Turin with a first diagnosis of HCC had AFP, PIVKA-II, and GPC-3 measured at diagnosis. Setting pathological cut-offs (AFP>10 ng/mL, PIVKA-II>200 mAU/mL, GPC-3>100 pg/mL) each patient received a "bio-score" based on the number of elevated biomarkers (0-3). Kaplan-Meier and Cox regression analyses were used to evaluate the relationship between the bio-score and OS. The bio-score demonstrated a significant association with OS (p<0.001), with higher scores correlating with worse outcomes. Patients with a bio-score of 3 had the poorest survival, while lower scores were associated with progressively better survival rates (Figure-1). In the multivariate analysis (Table-1), the bio- score emerged as an independent predictor of OS (p=0.027-HR=5.316 for score "3"), overtaking individual biomarkers in predictive power. The other independent variables associated with OS at multivariate analysis were the BCLC stage (p<0.001), the presence of ascites (p=0.003), ALBI grade (p=0.007) and the number of lesions (p=0.036). Combining AFP, PIVKA-II, and GPC-3 as a composite biomarker score provides superior predictive accuracy for OS in HCC patients compared to individual biomarkers. This multi-biomarker approach could offer a valuable, noninvasive prognostic tool, allowing for more personalized management of HCC patients based on survival probability. Further studies are recommended to validate this model in larger [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

22. Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients

Author

Colombatto, P., primary, Damone, F., additional, Ricco, G, additional, Oliveri, F., additional, Civitano, L., additional, Romagnoli, V., additional, Cavallone, D., additional, Demirtas, C.O., additional, Boraschi, P., additional, Scalise, P., additional, Crocetti, L., additional, Bargellini, I., additional, Coco, B., additional, Salvati, A., additional, Surace, L., additional, Urbani, L., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2022
Full Text
View/download PDF

25. Modeling cancer cells and tumor vasculature dynamics by serum biomarkers in HCC patients with different response to TKIs, TACE and TARE suggests a synergistic effect of systemic and endovascular treatments

Author

Damone, F., Colombatto, P., Ricco, G., Oliveri, F., Civitano, L., Romagnoli, V., Cavallone, D., Demirtas, C.O., Boraschi, P., Scalise, P., Crocetti, L., Bozzi, E., Coco, B., Salvati, A., Surace, L., Boni, G., Bonino, F., and Brunetto, M.R.

Published
2024
Full Text
View/download PDF

31. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Schiff, E. Schinazi, R. Sebastiani, G. Seguin-Devaux, C. Shanmugam, R.P. Sharara, A. Shilton, S. Shouval, D. Sievert, W. Simonova, M. Sohrabpour, A.A. Sonderup, M. Soza, A. Wendy Spearman, C. Steinfurth, N. Sulkowski, M. Tan, S.-S. Tanaka, J. Tashi, D. Thein, H.-H. Thompson, P. Tolmane, I. Toy, M. Valantinas, J. Van de Vijver, D. Vélez-Möller, P. Vince, A. Waked, I. Wang, S. Wedemeyer, H. Wong, V. Xie, Q. Yamada, S. Yang, H.-I. Yesmembetov, K. Yilmaz, Y. Younossi, Z. Yu, M.-L. Yuen, M.-F. Yurdaydin, C. Yusuf, A. Zekry, A. Zeuzem, S. Polaris Observatory Collaborators

Subjects
digestive system diseases
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

33. OC.04.9 A SINGLE CENTER, LARGE LONG TERM COHORT STUDY OF THE RELATIONS BETWEEN MUTATIONS IN BASIC-CORE-PROMOTER AND PRE-C REGIONS OF HEPATITIS B VIRUS DNA AND CLINICPATHOLOGIC OUTCOME OF HBEAG-NEGATIVE/ANTI-HBEPOSITIVE PHASE

Author

Cavallone, D., primary, Ricco, G., additional, Flichman, D., additional, Moriconi, F., additional, Colombatto, P., additional, Bleve, P., additional, Coco, B., additional, Oliveri, F., additional, Romagnoli, V., additional, Salvati, A., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

35. AF.84 BIOIMAGING, BIOCHEMICAL AND GENETIC MARKERS TO STRATIFY PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CLINICAL PRACTICE: A SINGLE CENTER COHORT STUDY

Author

Salvati, A., primary, De Rosa, L., additional, Faita, F., additional, Cavallone, D., additional, Ricco, G., additional, Colombatto, P., additional, Coco, B., additional, Romagnoli, V., additional, Oliveri, F., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

36. AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB

Author

Colombatto, P., primary, Demirtas, C.O., additional, Ricco, G., additional, Civitano, L., additional, Boraschi, P., additional, Scalise, P., additional, Cavallone, D., additional, Oliveri, F., additional, Romagnoli, V., additional, Bleve, P., additional, Coco, B., additional, Salvati, A., additional, Urbani, L., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

37. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Sch and Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Sch

Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

38. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

Author

Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., Zeuzem S., Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., and Zeuzem S.

Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries' progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to <=5 per 100 000, reduce HBV prevalence among 1-year-olds to <=0.1%, reduce HBV and HCV mortality to <=5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.Copyright © 2020 John Wiley & Sons Ltd

Published
2021

39. Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis

Author

Bonino, F., Marcellin, P., Lau, G.K.K., Hadziyannis, S., Jin, R., Piratvisuth, T., Germanidis, G., Yurdaydin, C., Diago, M., Gurel, S., Lai, M.-Y., Brunetto, M.R., Farci, P., Popescu, M., and McCloud, P.

Subjects
Hepatitis B -- Care and treatment, Hepatitis B -- Patient outcomes, Hepatitis B -- Research, Peginterferon alfa-2a -- Dosage and administration, Peginterferon alfa-2a -- Research, Lamivudine -- Dosage and administration, Lamivudine -- Research, Drug therapy, Combination -- Patient outcomes, Drug therapy, Combination -- Research, Health
Published
2007

43. Enzootic calcinosis of sheep in Uruguay.

Author

García y Santos, C., primary, Capelli, A., additional, Sosa, S., additional, Pérez, W., additional, Domínguez, R., additional, Pereira, R., additional, Bonino, F., additional, Goyen, J. M., additional, and Alonso, E., additional

Published
2011
Full Text
View/download PDF

45. Modeling hepatocellular carcinoma cells dynamics by serolo-gical and imaging biomarkers in patients with response to sorafenib and/or regorafenib

Author

Colombatto, P., primary, Demirtas, C.O., additional, Ricco, G., additional, Civitano, L., additional, Boraschi, P., additional, Scalise, P., additional, Cavallone, D., additional, Oliveri, F., additional, Romagnoli, V., additional, Bleve, P., additional, Coco, B., additional, Salvati, A., additional, Urbani, L., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

47. A single center, large long-term cohort study of the relations between mutations in Basic-Core-Promoter and pre-C regions of Hepatitis B virus DNA and clinic-pathologic outcome of HBeAg-negative/anti-HBe-positive phase

Author

Cavallone, D., primary, Ricco, G., additional, Flichman, D., additional, Moriconi, F., additional, Colombatto, P., additional, Bleve, P., additional, Coco, B., additional, Oliveri, F., additional, Romagnoli, V., additional, Salvati, A., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2021
Full Text
View/download PDF

50. T06.01.10 DATA DRIVEN MODEL OF NEOPLASTIC CELLS DYNAMICS BY CIRCULATING AND IMAGING BIOMARKERS OF HEPATOCELLULAR CARCINOMA: A PROMISING TOOL FOR INDIVIDUALIZED THERAPY

Author

Colombatto, P., primary, Demirtas, C.O., additional, Ricco, G., additional, Civitano, L., additional, Boraschi, P., additional, Vagli, P., additional, Cavallone, D., additional, Oliveri, F., additional, Salvati, A., additional, Bleve, P., additional, Bonino, F., additional, and Brunetto, M.R., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results